Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2000

View Archived Issues

BioMedicines files IND for interferon omega

Cantab reports anticancer potential for OX-40 ligand

Guilford pursues novel approach to neuroprotection, licenses rights to newly discovered enzyme

Results of phase II Multikine cancer study promising

Small patient study indicates potential of baclofen in treating alcoholism

Hyseq advances two product candidates into preclinical studies during 1999

TKT achieves several milestones with three product platforms during 1999

Clinical development of new class of antibiotics begins at AVI BioPharma

NicOx initiates French phase I trial of new oral formulation of NCX-4016

SBIR grant awarded to NeoRx for lymphoma radioimmunotherapy research

Phase III data presented for Corixa's melanoma vaccine

Effective new antianginal agents under study at Lafon

Lafon presents piperazinone-based antithrombotic agents

Japanese team discovers new MDR ligands useful for CNS and related disorders

Potent EP1 receptor ligands in early development at Ono

Inhibitors of protein prenyltransferases remain a focus of R&D at Merck

Guanacastepene, a novel antibiotic from a fungal source active against MRSA and VREF

New selectin inhibitor SKK-60060 shows promise in treatment of uveitis

Lundbeck will market Sonata in the U.K.

Vanguard Medica updates status of pipeline projects following integration of Cerebrus

GABA analogues useful for insomnia

SPA-S-843 superior to amphotericin B in several in vitro assays

JTV-519 may provide cardioprotection by mimicking preconditioning

Athersys and Acorda announce CNS functional genomics collaboration

New emergency contraceptive option available for U.K. women

NCX-4016 and aspirin undergo direct comparison for antiinflammatory/analgesic effects

BIIE-0246, the first selective nonpeptide neuropeptide Y Y2 antagonist

Abgenix highlights 1999 developments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...